LEADER 01718nam 2200457 a 450 001 9910695600303321 005 20070104153858.0 035 $a(CKB)5470000002370763 035 $a(OCoLC)77529826 035 $a(EXLCZ)995470000002370763 100 $a20070104d2006 ua 0 101 0 $aeng 135 $aurmn|---||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aHurricane Katrina$b[electronic resource] $estatus of hospital inpatient and emergency departments in the Greater New Orleans area : report to congressional committees 210 1$a[Washington, D.C.] :$cU.S. Government Accountability Office,$d[2006] 215 $aii, 39 pages $cdigital, PDF file 300 $aTitle from title screen (viewed on Dec. 27, 2006). 300 $a"September 2006." 300 $aPaper version available from: U.S. Government Accountability Office, 441 G St., NW, Rm. LM, Washington, D.C. 20548. 300 $a"GAO-06-1003." 320 $aIncludes bibliographical references. 517 $aHurricane Katrina 606 $aHealth services accessibility$zLouisiana$zNew Orleans Region 606 $aHospital care$zLouisiana$zNew Orleans Region 606 $aHospitals$zLouisiana$zNew Orleans Region 606 $aHospitals$xEmergency services$zLouisiana$zNew Orleans Region 606 $aHurricane Katrina, 2005 615 0$aHealth services accessibility 615 0$aHospital care 615 0$aHospitals 615 0$aHospitals$xEmergency services 615 0$aHurricane Katrina, 2005. 801 0$bGPO 801 1$bGPO 906 $aBOOK 912 $a9910695600303321 996 $aHurricane Katrina$93120901 997 $aUNINA LEADER 07487nam 22005655 450 001 9910151814303321 005 20251116173343.0 010 $a81-322-2803-0 024 7 $a10.1007/978-81-322-2803-5 035 $a(CKB)3710000000953093 035 $a(DE-He213)978-81-322-2803-5 035 $a(MiAaPQ)EBC4745432 035 $a(PPN)197141552 035 $a(EXLCZ)993710000000953093 100 $a20161117d2016 u| 0 101 0 $aeng 135 $aurnn|008mamaa 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aMelatonin, Neuroprotective Agents and Antidepressant Therapy /$fedited by Francisco López-Muñoz, Venkataramanujam Srinivasan, Domenico de Berardis, Cecilio Álamo, Takahiro A. Kato 205 $a1st ed. 2016. 210 1$aNew Delhi :$cSpringer India :$cImprint: Springer,$d2016. 215 $a1 online resource (XXV, 921 p. 178 illus., 113 illus. in color.) 311 08$a81-322-2801-4 320 $aIncludes bibliographical references at the end of each chapters and index. 327 $aHistory of pineal gland as neuroendocrine organ and discovery of melatonin -- Bibliometric study of scientific research on melatonin during the last 25 years -- Neuroimaging of the pineal gland. Focus on Primary Insomnia -- Melatonin: Basic and clinical aspects -- Melatonin and melatonin receptors in neuroprotection -- Melatonin supplementation in neurodegenerative diseases: Current status -- Therapeutic potential of melatonin in combination with other drugs against neurodegeneration -- Melatonin, a neuroprotective agent: relevance for stress induced neuropsychiatric disorders -- Melatonin, sleep, circadian rhythm and mood disorders -- Melatonin induces antidepressant-like behavior by promotion of hippocampal neurogenesis -- Association between melatonin and neuroimmune diseases -- Melatonin in clinical states of patients with fibromyalgia syndrome -- Melatonin?s beneficial effects in hepatic injury -- Melatonin as a novel therapeutic agent against chemical warfare agents -- New galenic formulations of melatonin -- Melatonergic drug ramelteon in neurotherapeutics -- Melatonergic antidepressant agomelatine and its efficacy in depressive disorders -- Agomelatine, melatonin and depression -- Neuropsychological models of depression -- Chronobiology of mood disorders -- Bipolar disorders and biological rhythm -- Circadian clock genes and mood disorders -- Understanding the biologically adaptive side of mood disorders: a focus on affective temperaments -- Sleep abnormalities as diagnostic tool for major depressive disorder -- Depression: Correlations with thyroid hormones in major depressive disorder -- History of the discovery of antidepressant drugs -- Neurocognitive deficit in bipolar disorders -- Combination strategies in treatment-resistant depression -- Antidepressant drugs in elderly -- Antidepressant efficacy of escitalopram in major depressive disorder -- Antidepressant medications and suicide risk: What was the impact of FDA warning? -- Neurobiology and pharmacological prevention of suicide in mood disorders -- Antidepressants and anticonvulsants as adjuvant analgesics in chronic pain -- Genetic polymorphisms of cytochrome P450 enzymes and antidepressants -- Pharmacogenomics of antidepressant drugs -- Antidepressants modulate microglia beyond the neurotransmitters doctrine of mood disorders -- Brain-derived neurotrophic factor (BDNF) - TrkB signaling in depression: Biomarker and novel therapeutic target -- Targeting opioid receptors for innovative antidepressant therapies: rediscovering the opioid cure -- Prolactin and somatostatin responses to antidepressant therapy -- The role of vasopressin in anxiety and depression -- Ketamine: the glutamatergic antidepressant and its efficacy -- Acetylcholinergic nicotinic receptors as pharmacological targets for cognitive enhancement: emerging evidence from psychosis populations.-The glutamate mGluR5 receptor as a pharmacological target to enhance cognitive function: emerging evidence from psychosis models -- Corticotropin-releasing factor receptors as a potential target in the developments of antidepressant drugs -- Nitric oxide signaling in depression and antidepressant action -- The role of arrestins in the neuroprotective aspects of antidepressant drugs -- Antidepressant drugs and phosphodiesterases -- Effect of methylphenidate and atomoxetine on development of the brain -- S-Adenosyl-L-methionine for major depressive disorder -- The role of antiepileptic drugs in bipolar depression -- Melatonin and other neuroprotective agents target molecular mechanisms of disease in amyotrophic lateral sclerosis. 330 $aThis work is a guidebook for clinicians who are involved in treating depressive patients and also serves the research scientists who are working on the psychopharmacological mechanisms of antidepressant actions and psychopathological mechanisms underlying mood disorders. Mood disorders such as major depressive disorder (MDD), bipolar disorder (BPD) and seasonal affective disorder (SAD) are the most disabling disorders that are among the most expensive of all medical illnesses. The pathophysiology of mood disorders is very complex and involves many mechanisms like circadian rhythm disruption, sleep abnormalities, melatonin rhythm abnormalities and alterations in melatonin receptor mechanisms, abnormalities in monoaminergic neurotransmitter mechanisms, glutamatergic release mechanisms, hippocampal neurogenesis, and abnormal immune and cytokine release mechanisms. Many antidepressants that are in clinical use today including the recently introduced novel agents like agomelatine or other antidepressants cause clinical remission by resynchronizing disrupted circadian rhythms and melatonin receptor functions, enhancing monoaminergic neurotransmission, promoting hippocampal neurogenesis, and regulating immune mechanisms. This book explains various etiological factors that are involved in the pathogenesis of mood disorders and the mechanisms of therapeutic actions of antidepressants including the recently introduced agomelatine and other antidepressants that exhibit rapid onset of action with greater efficacy and fewer side effects. . 606 $aNeurology 606 $aPsychopharmacology 606 $aInternal medicine 606 $aNeurology$3https://scigraph.springernature.com/ontologies/product-market-codes/H36001 606 $aPsychopharmacology$3https://scigraph.springernature.com/ontologies/product-market-codes/H53010 606 $aInternal Medicine$3https://scigraph.springernature.com/ontologies/product-market-codes/H33002 615 0$aNeurology. 615 0$aPsychopharmacology. 615 0$aInternal medicine. 615 14$aNeurology. 615 24$aPsychopharmacology. 615 24$aInternal Medicine. 676 $a616.8 702 $aLo?pez-Mun?oz$b Francisco$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aSrinivasan$b Venkataramanujam$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $ade Berardis$b Domenico$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aA?lamo Gonza?lez$b Cecilio$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aKato$b Takahiro A$4edt$4http://id.loc.gov/vocabulary/relators/edt 906 $aBOOK 912 $a9910151814303321 996 $aMelatonin, Neuroprotective Agents and Antidepressant Therapy$92513359 997 $aUNINA